Neuroblastoma

The disparate prevalence of cardiovascular risk factors among adult Black and Hispanic survivors of childhood cancer was comparable to the disparities in the American general population, researchers reported.

A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.

Linda H. Malkas, PhD, remembers the day a photograph for a newspaper changed her life.

The FDA announced several regulatory actions the past few weeks.

September is Childhood Cancer Awareness Month.

Hispanic children with high-risk neuroblastoma had worse survival outcomes than other children with the disease despite receiving treatment on clinical trials with standardized protocols, according to study results.

The addition of the novel monoclonal antibody hu14.18K322A to induction chemotherapy significantly improved outcomes among children with newly diagnosed high-risk neuroblastoma, according to phase 2 study results.

Genetic alterations of ALK, including clonal mutations and amplifications, in high-risk neuroblastoma demonstrated utility as independent predictors of poorer survival, according to a study published in Journal of Clinical Oncology.

A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial.

American Association for Cancer Research presented its AACR Team Science Award to the St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team.